Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3003891A RSV Vaccine in Healthy Women
NCT02956837Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2016
- Primary completion
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV) (4 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Any Grade 2 and Grade 3 General Adverse Events, Number of Subjects With Grade 2 and Grade 3 Fever and 3 more. Started Nov 2016; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02956837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956837.